Diana Miguel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Diana Miguel has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Catarina Pinheiro
Clínica Universitária de Dermatologia, Faculdade de Medicina de Lisboa, Av. Professor Egas Moniz, 1649-035 Lisbon, Portugal
2 shared publications - Paulo Filipe
Serviço de Dermatologia, Unidade Local de Saúde Santa Maria (ULSSM), Hospital de Santa Maria, Lisboa, Portugal
2 shared publications Diogo Cruz
Clínica Universitária de Dermatologia, Faculdade de Medicina de Lisboa, Av. Professor Egas Moniz, 1649-035 Lisbon, Portugal
1 shared publicationJoana Antunes
Clínica Universitária de Dermatologia, Faculdade de Medicina de Lisboa, Av. Professor Egas Moniz, 1649-035 Lisbon, Portugal
1 shared publication- João Boavida Ferreira
Serviço de Oncologia Médica, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal
1 shared publication João Pedro Freitas
Faculdade de Medicina de Lisboa, Clinica Universitária de Dermatologia, Avenido Prof. Egas Moniz, 1649-035 Lisboa, Portugal
1 shared publication
Latest Publications
- Open Access
- 20 November 2012
- Published by Wiley in International Journal of Endocrinology
- Vol. 2012, 1-16
Mechanisms of Action of Topical Corticosteroids in Psoriasis
Psoriasis is a lifelong, chronic, and immune-mediated systemic disease, which affects approximately 1–3% of the Caucasian population. The different presentations of psoriasis require different approaches to treatment and appropriate prescriptions according to disease severity. The use of topical therapy remains a key component of the management of almost all psoriasis patients, and while mild disease is commonly treated only with topical agents, the use of topical therapy as adjuvant therapy in moderate-to-severe disease may also be helpful. This paper focuses on the cutaneous mechanisms of action of corticosteroids and on the currently available topical treatments, taking into account adverse effects, bioavailability, new combination treatments, and strategies to improve the safety of corticosteroids. It is established that the treatment choice should be tailored to match the individual patient’s needs and his/her expectations, prescribing to each patient the most suitable vehicle.
- 20 November 2012
- Published by Wiley in International Journal of Endocrinology
- Vol. 2012, 1-16
Open AccessMechanisms of Action of Topical Corticosteroids in Psoriasis
Psoriasis is a lifelong, chronic, and immune-mediated systemic disease, which affects approximately 1–3% of the Caucasian population. The different presentations of psoriasis require different approaches to treatment and appropriate prescriptions according to disease severity. The use of topical therapy remains a key component of the management of almost all psoriasis patients, and while mild disease is commonly treated only with topical agents, the use of topical therapy as adjuvant therapy in moderate-to-severe disease may also be helpful. This paper focuses on the cutaneous mechanisms of action of corticosteroids and on the currently available topical treatments, taking into account adverse effects, bioavailability, new combination treatments, and strategies to improve the safety of corticosteroids. It is established that the treatment choice should be tailored to match the individual patient’s needs and his/her expectations, prescribing to each patient the most suitable vehicle.
- Open Access
- 25 July 2012
- Published by Wiley in Autoimmune Diseases
- Vol. 2012, 1-15
Cutaneous Manifestations of Systemic Lupus Erythematosus
Systemic lupus erythematosus (SLE) is a multiorgan autoimmune disease of unknown etiology with many clinical manifestations. The skin is one of the target organs most variably affected by the disease. The American College of Rheumatology (ACR) established 11 criteria as a classificatory instrument to operationalise the definition of SLE in clinical trials. They were not intended to be used to diagnose individuals and do not do well in that capacity. Cutaneous lesions account for four of these 11 revised criteria of SLE. Skin lesions in patients with lupus may be specific or nonspecific. This paper covers the SLE-specific cutaneous changes: malar rash, discoid rash, photosensitivity, and oral mucosal lesions as well as SLE nonspecific skin manifestations, their pathophysiology, and management. A deeper thorough understanding of the cutaneous manifestations of SLE is essential for diagnosis, prognosis, and efficient management. Thus, dermatologists should cooperate with other specialties to provide optimal care of SLE patient.
- 25 July 2012
- Published by Wiley in Autoimmune Diseases
- Vol. 2012, 1-15
Open AccessCutaneous Manifestations of Systemic Lupus Erythematosus
Systemic lupus erythematosus (SLE) is a multiorgan autoimmune disease of unknown etiology with many clinical manifestations. The skin is one of the target organs most variably affected by the disease. The American College of Rheumatology (ACR) established 11 criteria as a classificatory instrument to operationalise the definition of SLE in clinical trials. They were not intended to be used to diagnose individuals and do not do well in that capacity. Cutaneous lesions account for four of these 11 revised criteria of SLE. Skin lesions in patients with lupus may be specific or nonspecific. This paper covers the SLE-specific cutaneous changes: malar rash, discoid rash, photosensitivity, and oral mucosal lesions as well as SLE nonspecific skin manifestations, their pathophysiology, and management. A deeper thorough understanding of the cutaneous manifestations of SLE is essential for diagnosis, prognosis, and efficient management. Thus, dermatologists should cooperate with other specialties to provide optimal care of SLE patient.